HIV nucleoside reverse transcriptase inhibitors

被引：23

作者：

Amblard, Franck ^{[1
]}

Patel, Dharmeshkumar ^{[1
]}

Michailidis, Eleftherios ^{[1
]}

Coats, Steven J. ^{[1
]}

Kasthuri, Mahesh ^{[1
]}

Biteau, Nicolas ^{[1
]}

Tber, Zahira ^{[1
]}

Ehteshami, Maryam ^{[1
]}

Schinazi, Raymond F. ^{[1
]}

机构：

[1] Emory Univ, Ctr ViroSci & Cure, Dept Pediat, Lab Biochem Pharmacol,Sch Med & Childrens Healthca, 1760 Haygood Dr, Atlanta, GA 30322 USA

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2022年 / 240卷

关键词：

Nucleoside; HIV; Inhibitors; RT; Reversetranscriptase; Prodrug; HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE PLUS LAMIVUDINE; CHRONIC HEPATITIS-B; TENOFOVIR ALAFENAMIDE; ANTIVIRAL ACTIVITY; PHARMACOKINETIC PROPERTIES; DRUG-RESISTANCE; IN-VITRO; INTRACELLULAR ACTIVATION; COMBINATION THERAPY;

D O I：

10.1016/j.ejmech.2022.114554

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

More than 40 years into the pandemic, HIV remains a global burden and as of now, there is no cure in sight. Fortunately, highly active antiretroviral therapy (HAART) has been developed to manage and suppress HIV infection. Combinations of two to three drugs targeting key viral proteins, including compounds inhibiting HIV reverse transcriptase (RT), have become the cornerstone of HIV treatment. This review discusses nucleoside reverse transcriptase inhibitors (NRTIs), including chain terminators, delayed chain terminators, nucleoside reverse transcriptase translocation inhibitors (NRTTIs), and nucleotide competing RT inhibitors (NcRTIs); focusing on their history, mechanism of action, resistance, and current clinical application, including long-acting regimens.

引用

页数：11

共 50 条

[1] Nucleoside reverse transcriptase inhibitors and HIV mutagenesis
Jewell, NA
Chen, RX
Raices, R
Mansky, LM
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (04) : 547 - 550
[2] New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections
Otto, MJ
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (05) : 431 - 436
[3] Hepatotoxicity of nucleoside reverse transcriptase inhibitors
Montessori, V
Harris, M
Montaner, JSG
SEMINARS IN LIVER DISEASE, 2003, 23 (02) : 167 - 171
[4] Lipodystrophy with nucleoside reverse transcriptase inhibitors
Reactions Weekly, 1999, 774 (1) : 5 - 5
[5] Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase
Sweeney, Zachary K.
Acharya, Sahaja
Briggs, Andrew
Dunn, James P.
Elworthy, Todd R.
Fretland, Jennifer
Giannetti, Anthony M.
Heilek, Gabrielle
Li, Yu
Kaiser, Ann C.
Martin, Michael
Saito, Y. David
Smith, Mark
Suh, Judy M.
Swallow, Steven
Wu, Jeffrey
Hang, Julie Q.
Zhou, Amy S.
Klumpp, Klaus
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (15) : 4348 - 4351
[6] Non-nucleoside inhibitors of HIV-1 reverse transcriptase
Proudfoot, JR
EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (08) : 971 - 982
[7] HIV-1 non-nucleoside reverse transcriptase inhibitors
Högberg, M
Morrison, I
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (08) : 1189 - 1199
[8] Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection
Akanbi, Maxwell O.
Scarci, Kimberly
Taiwo, Babafemi
Murphy, Robert L.
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (01) : 65 - 79
[9] New non nucleoside inhibitors of HIV1 reverse transcriptase
Levan, K
Georges, B
Hevesi, L
Boland, S
Cauvin, C
Durant, F
Demonte, D
Dewalque, S
Van Lint, C
Burny, A
XV INTERNATIONAL AIDS CONFERENCE: BASIC SCIENCE, 2004, : 65 - 67
[10] Mechanisms of resistance of HIV-1 reverse transcriptase to nucleoside and non-nucleoside inhibitors
Boyer, PL
Tantillo, C
Ding, J
Ferris, AL
Clark, P
Arnold, E
Hughes, SH
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 6 - 6

← 1 2 3 4 5 →